Literature DB >> 11136559

Susceptibility to oxidation of plasma low-density lipoprotein in X-linked adrenoleukodystrophy: effects of simvastatin treatment.

A Di Biase1, S Salvati, R Varí, C Avellino, F Sforza, M Cappa, R Masella.   

Abstract

This paper shows for the first time the higher oxidizability of low-density lipoprotein (LDL) in plasma from adrenoleukodystrophy (ALD) patients compared to that of control subjects. LDL oxidation susceptibility was assessed by conjugate diene formation, hydroperoxide and lipoperoxide formation, and electrophoretic mobility. Simvastatin therapy, an HMG-CoA reductase inhibitor, seems to be a protective pharmacological agent against the higher oxidizability of LDL in plasma from ALD patients. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11136559     DOI: 10.1006/mgme.2000.3100

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  4 in total

Review 1.  Oxidative Stress in Patients with X-Linked Adrenoleukodystrophy.

Authors:  Marion Deon; Desirèe P Marchetti; Bruna Donida; Moacir Wajner; Carmen Vargas
Journal:  Cell Mol Neurobiol       Date:  2015-07-14       Impact factor: 5.046

2.  Effects of L-mono methyl-arginine, N-acetyl-cysteine and diphenyleniodonium on free radical release in C6 glial cells enriched in hexacosenoic acid.

Authors:  Antonella Di Biase; Rita Di Benedetto; Serafina Salvati; Lucilla Attorri; Fabiana Leonardi; Donatella Pietraforte
Journal:  Neurochem Res       Date:  2005-02       Impact factor: 3.996

3.  Evaluation of antioxidant systems in pituitary-adrenal axis diseases.

Authors:  A Mancini; E Leone; A Silvestrini; R Festa; V Di Donna; L De Marinis; A Pontecorvi; G P Littarru; E Meucci
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

4.  Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin.

Authors:  Mushfiquddin Khan; Jaspreet Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2008-06-07       Impact factor: 5.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.